

## [294] AGI-134: SMALL MOLECULE INDUCING HYPER-ACUTE, MULTI-ARM IMMUNE RESPONSE TARGETING TUMOR-SPECIFIC NEOANTIGENS

**Irit Carmi Levy<sup>1</sup>, Ella Sorani<sup>1</sup>, Phil Serlin<sup>1</sup>, Abi Vainstein<sup>1</sup>, Stephen Shaw<sup>1</sup>, <sup>1</sup> Biolinerx**  
**ABSTRACT for Company Presentations**

- **Investment rationale**

BioLineRx is a publicly-traded (NASDAQ/TASE), clinical-stage company, primarily focused on oncology and immunology. BioLineRx has a strategic collaboration with Novartis for the co-development of selected drug candidates. BioLineRx has established immunotherapy collaborations with both Merck and Genentech with our lead asset BL-8040, and last year acquired Agalimmune Ltd., thereby bolstering the Company's presence in the immuno-oncology field with AGI-134. The presentation will focus on AGI-134, a highly innovative synthetic alpha-Gal immunotherapy in development for solid tumors.

- **Business Strategy**

BioLineRx's close ties with research institutions and biotechnology companies, both in Israel and globally, enable access to promising late pre-clinical/early clinical stage projects. BioLineRx in-licenses and leverage selected programs through advanced development, clinical trials and registration. The Company partners with medium and large-size pharmaceutical companies to complete the clinical development and commercialization.

- **Core Technology**

**AGI-134** is a synthetic alpha-Gal immunotherapy in development for solid tumors. This universal drug harnesses the body's pre-existing anti-Gal-antibodies to evoke a vaccine effect via a unique, hyper-acute, multi-arm mechanism, resulting in an anti-tumor response targeting patient's own specific tumor neoantigens. This response not only kills the tumor cells at the site of injection but also brings about a durable, follow-on anti-metastatic immune response.

- **Product Profile/Pipeline**

**AGI-134** has completed numerous pre-clinical studies. In mouse melanoma model, treatment with AGI-134 leads to regression of established primary tumors and protects from secondary tumor (metastases) development. Furthermore, a combination of AGI-134 and anti-PD-1 (immune checkpoint inhibitor), has demonstrated synergistic benefit in protection from secondary tumor growth.

- **What's Next?**

BioLineRx continuously looking for novel agents available for in-licensing, as well as strategic transactions and collaborations to allow synergy and maximize its potential for the benefit of patients. AGI-134 is expected to commence a first-in-man study in the first half of 2018.